The Role of Cost-Effectiveness Analysis in Defining Transfusion Medicine Policy
Government officials, administrators and physicians charged with providing a safe blood supply face a difficult dilemma. After enduring decades of hepatitis C (HCV) risk without effective means to detect carriage of the causative agent and after discovering the havoc that can be wrought by a lethal, blood-borne immunodeficiency virus with a long incubation period, enhanced donor screening and testing tools have reduced infectious disease risks in the allogeneic blood supply of industrialized nations to lower levels than ever enjoyed previously. At the same time, however, new opportunities for increasing the safety of the blood supply pose new risks and may consume large amounts of healthcare resources. Choosing the course to be followed in these new waters is not simple.
KeywordsViral Inactivation Allogeneic Transfusion Donor Screening Autologous Blood Donation Blood Safety
Unable to display preview. Download preview PDF.
- 1.Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA, and the Transfusion Safety Study Group. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991 ;31:4–11.Google Scholar
- 4.Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C vims infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995;35:903–10.PubMedCrossRefGoogle Scholar
- 5.Nelson KE, Ahmed F, Stambolis V, Ness PM, Yawn D, McAlister H. Incident hepatitis C virus (HCV) and hepatitis virus (HBV) infections in transfused cardiac surgery patients: Infection rates during different methods of donor screening. In Infectious disease testing for blood transfusions. Consensus development conference. Bethesda: National Institutes of Health, 1995.Google Scholar
- 7.Canadian Coordinating Office for Health Technology Assessment. Leukoreductiond costs. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998.Google Scholar
- 27.Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB and the Retrovirus Epidemiology in Donors Study (REDS). Declining yield of alanine aminotransferase for screening of blood donors for prevention of post-transfusion hepatitis B and C virus infection. Transfusion 1995;35:903–10.PubMedCrossRefGoogle Scholar
- 30.Korelitz JJ, Busch MP, Williams AE for the Retrovirus Epidemiology Donor Study. Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: Will the benefit of a new HIV test be offset by the numbers of higher-risk, test-seeking donors attracted to blood centers. Transfusion 1996;36:203–08.PubMedCrossRefGoogle Scholar
- 34.Schwartz LM. Woloshin S. Black WC. Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Int Med 1997;127:966–72.Google Scholar
- 37.Morgan MG. Risk analysis and management. Sci Am 1993;269:32–35, 38–41.Google Scholar